Precision Radiotherapy for Graves’ Ophthalmopathy Outcomes and Predictors of Response

Y. J. Li,X. Xie,H. Shi,Y. Luo,F. Wang

DOI: https://doi.org/10.1016/j.ijrobp.2019.06.1296

2019-01-01

Abstract:Radiation for Graves’ ophthalmopathy (GO) has traditionally utilized lateral opposed fields (LOF) or three-dimensional conformal radiotherapy (3DCRT) techniques. The current study was conducted to report clinical outcomes and therapeutic efficacy of intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) in treating GO patients. A total of 113 and 246 GO patients were treated with VMAT and IMRT (including 46 patients treated with the EDGE radiosurgery system) as the initial local therapy between July 2010 and May 2018. The radiation dose was 20Gy given in 10 fractions within 10 working days. Dosimetric comparison between the three radiation methods was conducted. Immediate and long-term treatment response was evaluated by GO severity score in each category of symptoms. Acute and chronic post-radiotherapy complications were also recorded to assess the safety. Logistic regression analysis was conducted to identify possible predictive factors for treatment response. Symptom severity score decreased significantly from the start of treatment to 6 months post-radiotherapy (P<0.01). In total, 184 (74.8%) and 79 (69.8%) patients in the IMRT and VMAT group experienced improvement of GO symptoms in the first 6 months, and only 10 (4.1%) and 7 (6.2%) patients in the two groups suffered recurrence of the GO symptoms during the subsequent follow-ups. Orbital pain, tearing and extraocular muscle dysfunction responded best to radiotherapy, while proptosis and blurred vision were the most refractory symptoms. Acute complications were minimal and self-limited, and mainly included intermittent eye redness (8.1%), increased milphosis or madarosis (20.8%), sideburns hair loss (17.3%), and pseudo-progression of GO symptoms (12.1%). Long-term complications included: chronic xerophthalmias (6.7%), cataract (1.4%), and were managed medically. Radiation retinopathy and secondary malignancy was not noted in the cohort. Although the dosimetric comparison suggested a significantly lower radiation dose to the lens and optic nerves among the patients receiving IMRT by EDGE system, we did not find significant difference in treatment outcomes and complications between the three radiation methods. Current smokers (OR 2.92, P=0.003) and symptom duration longer than 18 months (OR 3.17, P=0.012) were identified as independent predictive factors for non-response of GO to the treatments. Precision radiotherapy, including IMRT and VMAT, could serve as a viable option in treating GO, achieving satisfactory symptom control while minimizing acute and late post-radiotherapy complications.